The information you provide to the chat will be collected and recorded to improve your experience and for quality assurance. Please read our privacy policy to see how we are storing and protecting your data.
How can we help you today?
We're proud to receive a 2025 CDMO Leadership Award in the “Small Molecule Dosage Form - Global" category.
Search Patheon
Recent searches
Clear History
Suggestions
All Results
Recent searches
Clear History
Suggestions
All Results
Search
US | EN
Opportunities for innovation and flexibility in mRNA and LNP manufacturing
On-demand webinar
From global life-saving vaccines to personalized cancer therapies, messenger ribonucleic acid (mRNA) is being considered for a variety of clinical applications, creating diverse requirements for scale and dosage. To meet these varying needs, flexibility in the manufacturing process is critical, as drug developers must determine how to efficiently deliver high yields of quality mRNA while also balancing logistical and financial objectives.
Partnering with an adaptable and collaborative CDMO can be essential to navigating industry challenges and finding the best solution to bring your unique mRNA vaccine or therapeutic to market. In a recent webinar, we explored options within a standard mRNA/LNP manufacturing workflow and highlighted Thermo Fisher Scientific innovations to support varying production strategies and enhance your processes, including:
- Synthetic DNA vs. plasmid DNA for template generation
- Use of fit-for-purpose plasmid DNA-backbones
- Leveraging DOE principles for mRNA and LNP process development
- Scale up optimization in mRNA and LNP manufacturing
- Comprehensive analytical characterization